As of 2025-12-26, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -30.16. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 16,792.29 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -556.74 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 15.5x | 14.8x |
| Forward P/E multiples | 12.5x - 18.8x | 16.6x |
| Fair Price | (50.01) - (55.50) | (55.89) |
| Upside | -165.4% - -172.5% | -173.0% |
| Date | EV/EBITDA |
| 2025-12-24 | -30.16 |
| 2025-12-23 | -30.12 |
| 2025-12-22 | -30.36 |
| 2025-12-19 | -30.08 |
| 2025-12-18 | -29.33 |
| 2025-12-17 | -29.29 |
| 2025-12-16 | -29.87 |
| 2025-12-15 | -29.46 |
| 2025-12-12 | -29.68 |
| 2025-12-11 | -29.31 |
| 2025-12-10 | -28.84 |
| 2025-12-09 | -28.48 |
| 2025-12-08 | -29.37 |
| 2025-12-05 | -29.16 |
| 2025-12-04 | -29.55 |
| 2025-12-03 | -29.34 |
| 2025-12-02 | -28.41 |
| 2025-12-01 | -28.52 |
| 2025-11-28 | -28.60 |
| 2025-11-26 | -28.50 |
| 2025-11-25 | -28.12 |
| 2025-11-24 | -28.24 |
| 2025-11-21 | -27.25 |
| 2025-11-20 | -26.04 |
| 2025-11-19 | -26.36 |
| 2025-11-18 | -26.38 |
| 2025-11-17 | -26.83 |
| 2025-11-14 | -26.65 |
| 2025-11-13 | -26.19 |
| 2025-11-12 | -26.59 |
| 2025-11-11 | -26.72 |
| 2025-11-10 | -25.41 |
| 2025-11-07 | -25.06 |
| 2025-11-06 | -25.39 |
| 2025-11-05 | -25.36 |
| 2025-11-04 | -24.91 |
| 2025-11-03 | -25.13 |
| 2025-10-31 | -25.35 |
| 2025-10-30 | -25.61 |
| 2025-10-29 | -26.73 |
| 2025-10-28 | -26.00 |
| 2025-10-27 | -25.67 |
| 2025-10-24 | -22.45 |
| 2025-10-23 | -22.30 |
| 2025-10-22 | -22.10 |
| 2025-10-21 | -22.49 |
| 2025-10-20 | -23.14 |
| 2025-10-17 | -22.68 |
| 2025-10-16 | -22.72 |
| 2025-10-15 | -23.27 |